Study suggests later Type-1 diabetes diagnosis increases risk of death
WASHINGTON According to the journal Diabetes Care, people diagnosed with Type 1 diabetes in young adulthood are at a greater risk for death than those diagnosed in childhood.
A study of over 4,200 patients showed that, of these patients, 3349 were diagnosed between the ages of 0 and 14 years and 897 were diagnosed between the ages of 15 and 29 years. The younger group was followed for an average of 12.8 years, and the older group was followed for an average of 8.3 years.
During the course of the study, 108 patients died, including 74 in the younger group and 34 in the older group. Of the 108 deaths, 47 resulted from diabetes complications.
Overall, the diabetics in the study were 4.7 times more likely to die during follow-up than similar-aged individuals drawn from the general population.
The relative death risk, however, differed for younger and older diabetic patients. In individuals between 15 and 29 years of age, diabetes increased the risk of death by 6.2-fold, whereas in younger people, the disease raised the risk by 4.2-fold. The risk of death increased with increasing disease duration, the report indicates.
Bystolic fulfills pharmacists’ desire for a new beta-blocker
NEW YORK Forest Laboratories and Mylan’s new, once-daily hypertension drug Bystolic now is available in pharmacies nationwide.
A recent survey showed that out of 20,000 retail pharmacists, 78 percent felt there was a need for a beta-blocker with an improved tolerability profile.
More than 2,000 people received Bystolic (nebivolol) during clinical trials. The drug’s efficacy was similar to that of other approved beta-blockers, the FDA said. The most common reported side effects were headache, fatigue, dizziness and diarrhea.
Hypertension affects about 72 million adults in America.
Tenn. pharmacy school receives $600,000 grant
NASHVILLE, Tenn. Lipscomb University has received a $600,000 grant from The Memorial Foundation to support the school’s new $10.1 million pharmacy school, which will receive its first class in August, according to published reports. The Lipscomb College of Pharmacy has accepted 75 students in its first class.
The money will be used to build three patient support laboratories where students will learn to compound and prepare drugs, carry out experiments and examine and assess patients.
The school will be located in the Burton Health Sciences Center. In honor of the foundation’s grant the labs will be named The Memorial Foundation Pharmacy Practice Center.
“We believe it is a good investment for the community and for those students who want to prepare for a career in pharmacy,” said J.D. Elliott, president of The Memorial Foundation.